

currently being evaluated in clinical trials.

This technology involves the development of a less immunogenic form of anti-CD22 immunotoxins. Specifically, the inventors have removed all of domain Ib and the majority of domain II from the PE38 portion of the immunotoxin. The resulting construct maintains a similar cytotoxicity to the larger immunotoxin, but with lowered immunogenicity.

*Application:* Treatment of cancers associated with the increased expression of CD22, such as leukemia and lymphoma.

*Advantages:* Less immunogenic immunotoxin results in improved cytotoxicity; Targeted therapy decreases non-specific killing of non-cancerous cells.

*Inventors:* Ira Pastan (NCI) *et al.*

*Patent Status:* U.S. Provisional Application No. 60/969,929 filed 09 Sep 2007 (HHS Reference No. E-292-2007/0-US-01).

*Licensing Contact:* David A. Lambertson, PhD; 301-435-4632; [lambertson@mail.nih.gov](mailto:lambertson@mail.nih.gov).

### **The Combination of Anti-CD22 Immunotoxins With Standard Chemotherapeutic Agents on a Human Burkitt Lymphoma Cell Line**

*Description of Technology:* The treatment of hematological malignancies has been a major public health challenge because patients frequently do not respond to conventional therapies with long-term complete remission. However, current therapies are associated with multiple toxicities, suggesting that new therapies are needed.

In the past several years immunotoxins have been developed as an alternative approach to treat different malignancies. Since hematological malignancies are readily accessible via the blood stream, immunotoxins represent a viable therapeutic approach. Furthermore, immunotoxins have the potential for decreased nonspecific toxicity, suggesting these agents could lead to improved cancer therapies.

This technology relates to new combination therapies using an immunotoxin and chemotherapeutic agent. Specifically, the anti-CD22 immunotoxin HA22 has been used in combination with 4 different chemotherapeutic agents: Taxol, cisplatin, etoposide and doxorubicin. The combinations were shown to have a synergistic effect when examined in both *in vitro* cell models and *in vivo* animal models. As a result, it may be possible for this combination therapy to

overcome previous shortcomings seen with chemotherapy treatment alone.

*Application:* Treatment of cancers associated with the increased expression of CD22, such as leukemia and lymphoma.

*Advantages:* Uses a combination of agents previously shown to be effective in killing cancer cells; Combination of immunotoxins and chemotherapeutics showed a synergistic effect, suggesting the combination offers distinct advantages of the use of either agent alone.

*Inventors:* Ira Pastan (NCI) *et al.*

*Patent Status:* PCT Application No. PCT/US2008/002747 filed 28 Feb 2008 (HHS Reference No. E-132-2007/2-PCT-01).

*Licensing Contact:* David A. Lambertson, PhD; 301-435-4632; [lambertson@mail.nih.gov](mailto:lambertson@mail.nih.gov).

Dated: May 23, 2008.

#### **Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. E8-12291 Filed 6-2-08; 8:45 am]

**BILLING CODE 4140-01-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Urologic Research Development.

*Date:* June 24, 2008.

*Time:* 8:30 a.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814.

*Contact Person:* Thomas A. Tatham, PhD, Scientific Review Officer, Review Branch,

DEA, NIDDK, National Institutes of Health, Room 760, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-3993, [tatham@mail.nih.gov](mailto:tatham@mail.nih.gov).

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Hepatitis C Ancillary Study.

*Date:* June 26, 2008.

*Time:* 2 p.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* D. G. Patel, PhD, Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 756, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-7682, [pateldg@nidddk.nih.gov](mailto:pateldg@nidddk.nih.gov).

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; The NIDDK Hepatitis B Clinical Research Network.

*Date:* July 10-11, 2008.

*Time:* 6 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Xiaodu Guo, MD, PhD, Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 761, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-4719, [guox@extra.nidddk.nih.gov](mailto:guox@extra.nidddk.nih.gov).

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Molecular Therapy Core Centers.

*Date:* July 22, 2008.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817.

*Contact Person:* Atul Sahai, PhD, Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 759, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-2242, [sahaia@nidddk.nih.gov](mailto:sahaia@nidddk.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: May 27, 2008.

#### **Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. E8-12284 Filed 6-2-08; 8:45 am]

**BILLING CODE 4140-01-P**